"6 months history not responded to first line treatments (ie medication with lidocaine, anticonvulsants, antidepressants) significant disability and distress" "All of the neuropathic pain beyond ...

Background Best current estimates of neuropathic pain (NeuP ... trials (three months/maximum tolerated); outcomes of treatment (pain severity, quality of life). Further work needs to validate ...

MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments ... solutions for neuropathic pain without ...

Often seen as a safer alternative to opioids for the treatment of neuropathic pain, gabapentinoid use increased eightfold between 2012 and 2018, with one in seven Australians aged 80 and older ...

Limitations of Current FDA-Approved Treatments and the Need for Innovation: Neuropathic pain is a growing global health concern, with increasing prevalence linked to conditions like diabetes ...

"Ketamir-2 has the potential not only to address neuropathic pain but also to make a significant impact in the treatment of PTSD and depression. Our goal is to ensure that those who need it most ...

"Ketamir-2 has the potential not only to address neuropathic pain but also to make a significant impact in the treatment of PTSD and depression. Our goal is to ensure that those who need it most have ...

With the potential to avoid sedation and cognitive impairment, Ketamir-2 offers an improved quality of life compared to currently available treatments. Expanding Ketamir-2's Potential Beyond ...